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. In contrast to conventional cytotoxic agents, which directly target cancer cells, a major goal of cancer immunotherapy is to alleviate tumour-associated suppression of anticancer immune responses. A substantial portion of cancer immunotherapy research over the past decade has focused on heightening the functions of effector T cells, which play a direct role in recognizing tumourassociated antigens and in mediating tumoricidal responses 5 . In this context, both tumour antigen-based therapeutic cancer vaccines and engineered chimeric antigen receptor (CAR) T cell therapies rely on the formation of antigen-specific T lymphocyte clones that can recognize and eradicate tumours harbouring a particular antigen or a mutant protein. Both approaches have shown promise in preclinical studies and early-phase clinical trials; in particular, CAR T cell therapy has demonstrated potential as a treatment for haematological malignancies [6] [7] [8] [9] [10] [11] [12] . However, immune tumour vascular remodelling, metabolic homeostasis and immune reprogramming. Together, these elements establish a positive feedback loop in which changes in one will reinforce the effects of the others. Understanding the mutual regulation among these processes and their collective effects on promoting antitumour immunity is crucial for elucidating the mechanisms of tumour immune evasion and for developing effective combinational cancer immunotherapies.
The aberrant tumour vasculature
The stimulation of local and systemic antitumour immune responses is essential for successful cancer immunotherapy 19 .
For activated immune cells to eradicate cancer cells, they first need to penetrate deep into the tumour parenchyma and identify cancer cells as their intended targets. Once inside the tumour, immune cells also need to overcome many of the immunosuppressive mechanisms within the TME [20] [21] [22] .
Effect on immune cell infiltration.
Immune cells, like nutrients or oxygen, rely on a functional vascular network to enter tissues 23 . The hypoxic environment within solid tumours induces the continued production of proangiogenic factors, such as vascular endothelial growth factor (VEGF), transforming growth factor-β (TGFβ), fibroblast growth factor (FGF) and plateletderived growth factor (PDGF) [24] [25] [26] . This results in an imbalance between the levels of proangiogenic and antiangiogenic factors, which are tightly regulated in healthy tissues, and promotes rapid but aberrant tumour blood vessel formation 24, 27, 28 . Morphologically, tumour blood vessels are tortuous, dilated and unevenly distributed, with adjacent endothelial cells being loosely attached to one another. Pericytes, which surround the blood vessels and regulate vascular permeability, are usually detached from the endothelial cells, resulting in leaky tumour blood vessels that are characterized by dysfunctional flow characteristics 22, 28 . Tumour-associated endothelial cells also express lower levels of cell adhesion molecules, such as vascular cell adhesion protein 1 (VCAM1) and intercellular adhesion molecule 1 (ICAM1), which checkpoint inhibitors target inhibitory ligand-receptor interactions between T cells and immunosuppressive cells within the tumour microenvironment (TME), in particular, interactions mediated by tumour cells 13 . Ipilimumab, a monoclonal antibody that targets cytotoxic T lymphocyte antigen 4 (CTLA4) and antibodies blocking the programmed cell death protein 1 (PD1)-programmed cell death 1 ligand 1 (PDL1) axis, has led to remarkable clinical responses in several types of metastatic cancer, for example, melanoma 14 , non-small-cell lung cancer (NSCLC) 15, 16 , Merkel cell carcinoma 17 and renal cell carcinoma 18 . In this Opinion article, we highlight emerging evidence showing that cancer immunotherapies, such as immune checkpoint blockade, can promote T lymphocyte activation beyond modulating the stimulatory-inhibitory axis and that this activation may extend to normalize the immunosuppressive TME. We propose that a reciprocal regulation between immune cells and the tumour vasculature is critical in dictating the antitumour effect of cancer immunotherapy and forms the basis of a larger interacting network consisting of Abstract | The vasculature of tumours is highly abnormal and dysfunctional. Consequently, immune effector cells have an impaired ability to penetrate solid tumours and often exhibit compromised functions. Normalization of the tumour vasculature can enhance tissue perfusion and improve immune effector cell infiltration, leading to immunotherapy potentiation. However, recent studies have demonstrated that the stimulation of immune cell functions can also help to normalize tumour vessels. In this Opinion article, we propose that the reciprocal regulation between tumour vascular normalization and immune reprogramming forms a reinforcing loop that reconditions the tumour immune microenvironment to induce durable antitumour immunity. A deeper understanding of these pathways could pave the way for identifying new biomarkers and developing more effective combination treatment strategies for patients with cancer.
promotes endothelial anergy and reduces the trafficking of immune effector cells into tumours [29] [30] [31] [32] . Together, the structural and functional abnormalities of tumour blood vessels decrease the recruitment of immune effector cells, thus limiting the effectiveness of cancer immunotherapies (FIG. 1) . Strategies to convert a 'cold' tumour that is devoid of immune effector cells into a 'hot' tumour by increasing tumour infiltration of T lymphocytes are the focus of active research, which aims to increase the effectiveness of cancer immunotherapies [33] [34] [35] . It is not surprising that poorly vascularized tumours, for example, pancreatic adenocarcinoma, which is densely packed with fibrous stroma with a sparse immune cell presence, are often highly resistant to cancer immunotherapies 36 . hypoxia indirectly increases the accumulation of regulatory T (T reg ) cells within the TME by upregulating the expression of the chemoattractant chemokines CC-chemokine ligand 22 (CCL22) and CCL28 on tumour cells and TAMs 41, 42 . Furthermore, hypoxia promotes the secretion of immunosuppressive factors such as VEGF, TGFβ and IL-10 from resident immunosuppressive cells within the TME 22, 43, 44 . Hypoxia also induces the expression of immune checkpoint molecules such as PDL1 on tumour cells 45 , as well as the expression of PDL1, T cell immunoglobulin and mucin-domain containing-3 (TIM-3; also known as HAVCR2) and CTLA4 on TAMs, MDSCs and T reg cells. Moreover, through VEGF, hypoxia can indirectly upregulate PD1 expression on CD8 + T lymphocytes, thus further inhibiting Effect on tumour immune micro environment. In addition to having direct effects on immune cell adhesion and extravasation, the abnormal tumour vasculature also indirectly antagonizes the effectiveness of cancer immunotherapy by promoting TME-mediated immune suppression. The impaired perfusion capacity of tumour blood vessels helps to create a highly hypoxic TME 22, 25 . Hypoxia contributes to immunosuppression via several mechanisms (the regulation of immunity by hypoxia is reviewed in REF. 37 ). First, hypoxia promotes the accumulation of myeloid-derived suppressor cells (MDSCs) and facilitates the differentiation and polarization of tumour-associated macrophages (TAMs) into an immunosuppressive M2-like phenotype [38] [39] [40] . Second, Nature Reviews | Immunology 
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immune effector cell activation and function [46] [47] [48] [49] [50] [51] (FIG. 1) . Finally, hypoxia and tumour cell necrosis increase the extracellular concentrations of the immune-inhibitory metabolites adenosine and lactate [52] [53] [54] [55] . The accumulation of lactate further leads to metabolic lactic acidosis (a low pH in the blood owing to a build-up of lactic acid) and results in impaired cytotoxic T cell functions by interfering with T cell receptor (TCR)-triggered production of IFNγ 56 . These processes act together to inhibit effector immune cell maturation and to promote T cell anergy and exhaustion (FIG. 1) . Therefore, dysfunctional tumour vessels have a major role in contributing to the immunosuppressive nature of the TME and countering the effect of cancer immunotherapies.
Tumour vascular normalization
Given that the abnormal tumour vasculature promotes immune suppression within the TME, strategies that normalize these aberrant blood vessels may therefore restore immune cell functions and facilitate their antitumour activities. Although initially proposed as a way to improve the delivery of systemic drugs into tumours 27, 57, 58 , the process of vascular normalization was recently shown to potentiate cancer immunotherapy by promoting immune cell infiltration into tumours and reducing the immunosuppressive elements within the TME.
Genetically induced vascular normalization improves immunotherapy.
Genetic disruption of regulator of G protein signalling 5 (Rgs5) expression in mice caused immature pericytes (positive for PDGF receptor-β) to become mature pericytes (positive for both α-smooth muscle actin (αSMA; also known as ACTA2 in humans) and neural/glial antigen 2 (NG2; also known as CSPG4 in humans)) without affecting their overall coverage of the vasculature. This phenotypic change within tumour vessels consequently reduced tumour tissue hypoxia and vascular leakiness, leading to an influx of immune effector cells into the tumour parenchyma 59 . This study proposed that the reductions in intratumoural pressure and hypoxia owing to pericyte maturation were the main reasons for the increased T cell entry. However, vasculature normalization also results in an increased and more uniform distribution of adhesion molecules on the luminal surface of endothelial cells lining the tumour blood vessels, thus allowing more efficient immune be seen whether the absence of CD8 + T cells will also abrogate the accompanying vascular normalization effect 70 . Interestingly, the dual blockade of ANG2 and VEGF upregulated PDL1 expression in tumour endothelial cells via IFNγ 70 . This observation raises the possibility that resistance to antiangiogenic therapy may arise, at least in part, owing to the development of adaptive immunosuppressive processes within tumours 70, 72 . Furthermore, IFNγ can induce both PDL1-dependent and PDL1-independent resistance within tumours in the setting of immune checkpoint blockade 73 . Together, these findings further highlight the intricate relationship between immune cells and tumour blood vessels and provide new rationales for combining antiangiogenic treatments with immunotherapies. The exact mechanism by which the proangiogenic eosinophils induce vessel normalization is unclear, but it may be that they act through the polarization of TAMs into the M1-like phenotype via eosinophil-derived IFNγ and tumour necrosis factor (TNF) signalling, resulting in decreased VEGF production. The normalized blood vessels improve T cell infiltration, which results in a positive feedback loop that facilitates further M1-like macrophage polarization, vessel normalization and VCAM1 expression on endothelial cells to promote more efficient T cell entry 74 . Together, these studies confirm that vascular normalization has an immune-supportive role in improving antitumour immunity through a multitude of mechanisms, including reducing tumour tissue hypoxia, improving the access of tumour-infiltrating T lymphocytes to tumour cells and polarizing immunosuppressive cells towards immune-stimulatory phenotypes.
Immune-vascular crosstalk
The interplay between tumour blood vessel remodelling and tumour immune microenvironment reprogramming has led to studies examining the effect of vascular normalization on immune checkpoint blockade and vice versa 70, 72, 75 . In CD4 + T cell-deficient mice, pericyte coverage of blood vessels was reduced cell docking and rolling, both of which facilitate immune cell infiltration into tumours 60 .
Therapeutically induced vascular normalization improves immunotherapy.
Beyond genetic manipulations, the therapeutic blockade of proangiogenic factors can also normalize tumour vasculature and improve cancer immunotherapies. Traditional high-dose antiangiogenic therapy destroys tumour vessels, leading to further hypoxia and inhibition of immune cell recruitment. However, appropriate low-dose antiangiogenic therapy against VEGF and/or VEGF receptor (VEGFR) was found to induce tumour vascular normalization, reduce hypoxia, facilitate tumour infiltration of CD8 + T lymphocytes and potentiate cancer immunotherapy [61] [62] [63] [64] [65] . The importance of hypoxia in promoting immune suppression within solid tumours was further illustrated by a recent study demonstrating that respiratory hyperoxia induced by breathing a high concentration (60%) of oxygen alone could convert the TME from an immunosuppressive to an immunosupportive phenotype by decreasing intratumoural hypoxia and concentrations of extracellular adenosine 66 . As a result, respiratory hyperoxia resulted in the regression of spontaneously developed tumours in a T cell-dependent and natural killer (NK) cell-dependent manner 66 . Although earlier studies of tumour vascular normalization mostly focused on disruption of the VEGF-VEGFR axis, recent studies have revealed the angiopoietin (ANG)-angiopoietin 1 receptor (TIE2; also known as TEK) signalling pathway as a promising new target for normalizing tumour vessels 67 . Simultaneous blockade of angiopoietin 2 (ANG2) and activation of TIE2 signalling normalized tumour vessels and induced favourable immunological alterations within the TME 57 . Moreover, dual targeting of ANG2 and VEGF signalling pathways often results in improved vascular normalization relative to VEGF inhibition alone 68, 69 , and in various tumour models such targeting improved the effects of PD1 blockade 70 . The vascular normalization effect of dual ANG2 and VEGF blockade was associated with more efficient lymphocyte priming by antigen-presenting cells, TAM polarization to an M1-like phenotype and accumulation of activated, IFNγ-expressing CD8 + T cells within the perivascular space 70, 71 . Although depletion of CD8 + T cells completely eliminated the antitumour effects of ANG2 and VEGF blockade, it remains to and tumour tissue hypoxia was increased in breast tumour models, thus indicating that a lack of CD4 + T cells causes vascular abnormalities 75 . Treatment with dual anti-CTLA4 and anti-PD1 therapy, which had been thought to mainly affect T cells [76] [77] [78] [79] [80] [81] , induced tumour vessel normalization 75 . Although it is well known that immune cell populations possess antiangiogenic and/or proangiogenic activities [82] [83] [84] , the results of this study suggest that the antitumour effects of immune checkpoint blockade also stem from its ability to remodel the tumour vasculature 75 .
example, the conditions required for immuno therapy-induced vascular normalization, the duration of the response and the differences between it, and the vascular normalization mediated by antiangiogenic therapy remain unclear. In addition, the distinct effects of CD4 + and CD8 + T cell populations on tumour blood vessels in the setting of immune checkpoint blockade need further analysis. Thus far, the role of CD4 + T cells on tumour vessels has been elucidated through genetic manipulation or antibody-mediated depletion, in which tumour implantation occurred in the absence of CD4 + T cells 75 . It is well known that tissue hypoxia increases as a tumour grows 28 , resulting in TME changes that increase the T reg cell population within the tumour 41, 42, 52 . Several elegant studies have demonstrated that T reg cells A feedback loop of vascular normalization and immune reprogramming. This unexpected action of immune checkpoint inhibitors thus completes a positive feedback loop, in which immune checkpoint inhibitors activate T cells to normalize tumour blood vessels, resulting in the polarization of the immunosuppressive TME into an immune-supportive environment. This in turn facilitates the expansion and improves the functions of intratumoural effector T cells, thus leading to more vascular and TME remodelling, which ultimately produce long-term tumour control (FIG. 2) . can promote tumour angiogenesis and that T reg cell depletion activates CD8 + T cells and induces vascular normalization 42, 74 . Therefore, the tumour vascular normalization effect of immune checkpoint blockade is likely to be a dynamic process that involves different immune cell populations at different stages of tumour development.
Molecular mechanisms of the feedback loop.
At the molecular level, the interconnection between angiogenesis and immune activation relies on dual-functional signalling of many proangiogenic factors and immune regulator proteins. Previous studies have demonstrated that proangiogenic factors are usually immuno suppressive, whereas immune effector cells and antitumour cytokines possess angiostatic effects. For example, potent angiogenic factors (such as, VEGF, which is secreted by tumour and stromal cells) can interfere with both the maturation of dendritic cells from CD34 + precursors and the development of T lymphocytes [85] [86] [87] [88] . By contrast, major mediators of antitumour immune responses such as IFNγ, CXC-chemokine ligand 9 (CXCL9), CXCL10 and TNF also inhibit tumour angiogenesis [89] [90] [91] [92] [93] . Moreover, IFNγ is a major mediator of antitumour immunity with robust antiangiogenic activity 3, 83, 84, 93 . A recent study induced IFNγ expression in murine fibrosarcoma and adenocarcinoma cells and selectively expressed IFNγ receptor in specific stromal cell types, including myeloid cells, fibroblasts, T cells and endothelial cells; this study found that IFNγ directly promoted tumour vessel regression and blood flow arrest via its interactions with IFNγ receptors on tumour endothelial cells, leading to intratumoural ischaemia and subsequent collapse of the tumour 92 . The apparent discrepancy between this finding and the recent evidence that IFNγ promoted vessel normalization 75 could be explained by potential differences in the exposure of endothelial cells to IFNγ 75, 92 . The induction of IFNγ expression in tumour cells produced high systemic IFNγ concentrations (~10 ng per ml), which were maintained for a more extended period than the transient IFNγ elevation that can be elicited by adoptively transferred antigenspecific T cells 92 . Therefore, it is likely that the inducible IFNγ system produced more intense and sustained antiangiogenic effects on tumour blood vessels than those seen with IFNγ stimulation from immune checkpoint blockade 75, 92 . Excess polarize immunosuppressive myeloid cells within tumours have been investigated to normalize tumour vasculatures. For example, histidine-rich glycoprotein was found to induce TAM polarization away from the immunosuppressive phenotype by downregulating macrophage-derived PGF. This response resulted in sustained tumour vascular normalization that inhibited tumour growth and metastases 101, 102 .
New biomarkers for immuno-oncology
The discovery that activated T cells can induce morphological and functional tumour vessel normalization in the setting of immune checkpoint blockade provides a new opportunity to identify novel biomarkers for cancer immunotherapy 103 .
Serumbased biomarkers for immuno oncology. Serum-based biomarkers reflecting the functional status of tumour blood vessels were previously used to monitor responses to angiogenic therapies 104, 105 and may now be explored as predictors of response to cancer immunotherapies. Serum levels of ANG2, a vessel-destabilizing ligand of TIE2 and a critical regulator of blood vessel maturation 106 , were found to inversely correlate with both clinical response rate and survival in patients with melanoma treated with the anti-CTLA4 antibody ipilimumab 107 . Similarly, humoral responses against proangiogenic cytokines including ANG2 and VEGF were found to predict long-term remission and survival in patients with acute myeloid leukaemia who had received tumour cell vaccines after allogeneic haematopoietic stem cell transplantation and also in patients with NSCLC treated with tumour vaccines 108, 109 . Together, these findings support the interconnected relationship between tumour vascular remodelling and the generation of antitumour immune responses, and they further highlight the potential role of using vascular-related biomarkers as a surrogate to predict clinical responses to cancer immunotherapies.
Vesselbased biomarkers for immuno oncology. Beyond circulating biomarkers, functional measurements of vascular changes with Doppler ultrasonography, perfusion scans or dynamic contrastenhanced magnetic resonance imaging 110, 111 may also provide important information regarding the changes that occur within the TME as a surrogate for tumour responses to immune checkpoint inhibitors (FIG. 3) . These noninvasive measurements also allow longitudinal monitoring during antiangiogenic activities mediated by both higher-dose and prolonged IFNγ exposure likely promote the transition from vascular normalization to vessel regression, a phenomenon that was also observed in previous studies using anti-VEGFR2 agents 61, 63 . In addition to IFNγ, T helper 1 (T H 1)-type chemokines (such as CXCL9 and CXCL10) can produce angiostatic effects as well as act as chemoattractants for effector T cells 33 . Human microvascular endothelial cells that express high levels of CXC-chemokine receptor 3 (CXCR3), the receptor for the angiostatic chemokines CXCL4, CXCL9, CXCL10 and CXCL11, were found to exhibit low rates of proliferation and high rates of apoptosis as well as a decreased ability to undergo tube-like vessel formation 89 . Several recent studies revealed that the elevated levels of histone and DNA methylation within tumours and the activation of intrinsic oncogenic signalling suppressed the expression of T H 1-type chemokines and resulted in a cold tumour type that was resistant to immunotherapy 33, 94, 95 . Treatment with epigenetic modulators was found to restore the expression of CXCL9 and CXCL10, promote CD8 + T cell tumour infiltration and increase the efficacy of immune checkpoint therapy 94 . These studies further underscore the complexity of the interactions between immune cells and tumour blood vessels at the genetic and molecular levels.
Finally, immunosuppressive cell populations such as T reg cells, MDSCs and M2-like TAMs not only promote tumour immune evasion but also foster tumour angiogenesis by secreting VEGF, placenta growth factor (PGF), IL-1β, IL-6, FGF2, stromal cell-derived factor 1 (SDF1) and PDGF, among others 33, 93, 96, 97 . Both TAMs and MDSCs are often intimately associated with tumour blood vessels 98 and secrete membrane-bound or soluble proteases (for example, matrix metallo proteinase 2 (MMP2), MMP9 and MMP12), which facilitate the growth of tumour blood vessels by degrading the extracellular matrix and improving the availability of proangiogenic growth factors 99, 100 . Interestingly, MDSCs that reside within the perivascular space can adopt an endothelial cell-like morphology and express markers such as CD31 and VEGFR2, suggesting that these immature cells possess the potential to differentiate into cells that become part of the tumour vasculature 96, 97 . Therefore, strategies that deplete or therapy, a limitation that faces tissue-based biomarkers because of the need for repeat biopsies. Measurements of tumour vascular remodelling more closely reflect changes within the TME in the setting of immune checkpoint blockade therapy, which may not be perfectly represented by systemic biomarkers such as circulatory cytokine levels, immune cell subset counts or lactate dehydrogenase levels 103 . Finally, tumour vascularity 112 and the degree of perfusion impairment may also serve as predictors of response to cancer immunotherapy at baseline, before treatment is begun. These new imaging biomarkers can be incorporated into future clinical trial designs and can potentially be used to stratify patients for treatments, as has been successfully done for PDL1 expression in advanced-stage NSCLC 103 . Again, establishing robust vascular biomarkers for cancer immunotherapy requires carefully designed biomarker exploratory studies with independent validation and is still far from clinical translation at this time.
cooperative group trials are ongoing to study the usefulness of combining radiation with cancer immunotherapies. These studies are largely based on the premise that radiation can facilitate the release of tumour-associated antigens, which may help to broaden the antitumour responses in the setting of immune stimulation 116 . However, it is far from clear how the two regimens should be delivered in relation to one another (for example, concurrently versus sequentially) and what type of radiotherapy should be used (for example, conventionally fractionated, where a large number of treatments are delivered with small doses of radiation, versus hypofractionated or stereotactic radiotherapy, where a few large doses of radiation are used to ablate the tumour) to yield the best response 117, 118 . Ionizing radiation is known to induce changes within the tumour immune micro environment 35 , but the nature of these changes has not always been consistent. For example, studies using a single fraction of low-dose radiation (~2 Gy) have shown normalized tumour Nevertheless, noninvasive measurement techniques provide a unique opportunity to explore TME-based biomarkers on the basis of functional changes induced by immune checkpoint blockade therapy, which extend beyond traditional tumour cell and immune cell analyses.
Combination immunotherapies
The interdependence between vascular normalization and immune reprogramming provides a unique opportunity to identify new and more efficient combination therapy strategies to improve antitumour immunity. Since the first clinical trial of ipilimumab monotherapy for patients with advanced melanoma nearly a decade ago, research has focused on combining immunotherapies with standard-of-care chemotherapy or radiotherapy to achieve the optimal therapeutic effects 14, [113] [114] [115] . However, in some cases, it is unclear whether a mechanistic basis exists to support the specific combination regimen used. For example, several institutional and Nature Reviews | Immunology vasculatures and improved T cell recruitment by inducing nitric oxide synthase, inducible (NOS2) expression in TAMs in mouse and human pancreatic tumours 119, 120 . However, other studies have found that a single-fraction ablative dose of radiation (as high as 30 Gy) promotes increased CD8 + T cell infiltration and decreases levels of MDSCs in murine colorectal tumours 121 . It is unclear whether the differences in these findings mainly reflect variations in the tumour models used or are due to the involvement of distinct molecular processes. Nevertheless, the fact that stimulated T cells in the setting of immune checkpoint blockade also promote tumour vascular normalization, improve tissue perfusion and alleviate tumour hypoxia provides a strong rationale that mutually beneficial effects may exist between cancer immunotherapy and radiotherapy. Beyond the traditional belief that radiotherapy serves as an immune adjuvant 35 , it is now conceivable that immunotherapy may also have radio sensitizing effects by increasing oxygenation within the tumour, thus paving the way for future studies to examine this reciprocal effect.
The relationship between cancer immunotherapy and conventional systemic therapy also warrants a more detailed examination in light of these new findings. By normalizing the tumour vasculature and improving tissue perfusion, cancer immunotherapy may, at least in theory, improve the delivery of systemic agents into tumours 122 . However, similar to vascular normalization strategies using antiangiogenic agents, the optimal conditions needed to produce notable therapeutic benefits may be technically difficult to accomplish and may vary among different tumours and different patients 61 . Nevertheless, new mechanistic insights into the interplay between vascular normalization and immune reprogramming provide us with a theoretical foundation to explore new combination approaches using cancer immunotherapy and systemic therapies.
Vasculature and beyond
Vascular normalization can also lead to changes in the acellular components of the TME that may facilitate the infiltration and activation of immune effector cells to complement cancer immunotherapies. For example, increased tumour blood vessel permeability and decreased lymphatic drainage lead to an elevated intratumoural interstitial fluid pressure (IFP) 123 . This pathophysiological state in the TME makes TME. Further investigations into the effect of tumour vascular normalization on the ionic profiles within the TME are therefore needed to fully understand the reciprocal interactions between tumour blood vessel remodelling and immune reprogramming.
Outlook
Although the evaluation of antitumour immune responses has traditionally been focused on assessing the interactions between cancer and immune effector cells, growing evidence now suggests that other components of the TME also have critical roles in determining the effectiveness of cancer immunotherapies 22, 56, 128, 129 . The constituents of the TME form a sophisticated interaction network that ultimately determines the immune landscape within the TME. The complexity and heterogeneity of this immune TME require a systematic assessment of different molecular (for example, IFNγ, granzyme B and various cytokines), cellular (for example, CD8 + T cell activation and myeloid cell polarization), vascular (for example, vessel normalization and tissue perfusion) and acellular responses (for example, metabolic and ionic changes) to cancer immunotherapies. The finding of mutual regulation between tumour vascular normalization and immune reprogramming supports the notion that the antitumour effects of immune checkpoint inhibition may depend not only on the restoration of effector T cell functions within the TME but also on the normalization of the TME itself. Therefore, the effects of immune checkpoint blockade on the TME, such as the vascular changes that it induces, may provide novel variables with which to evaluate and predict cancer immunotherapy responses. The insights gained from studying this reciprocal regulation between immune stimulation and TME normalization have thus opened new avenues to understand how tumours undergo immune evasion and to identify strategies to further boost the antitumour effects of cancer immunotherapies.
it difficult for immune effector cells to enter the tumour parenchyma, and they accumulate primarily around the tumour edge 123 . By restoring the transluminal pressure gradient across tumour blood vessels, vascular normalization has been shown to decrease the IFP within the TME 28 , therefore reducing the restrictions on immune effector cell mobilization and tumoricidal functions.
Another potential benefit of tumour vascular normalization is through its effect on intratumoural lymphatic vessels. Elevated IFP may lead to the compression of intratumoural lymphatic vessels, which may be important for antigen-presenting cells to home to regional lymph nodes and prime T cells 124 . Previous studies of tumour vascular normalization showed that despite the restoration of blood flow within previously compressed blood vessels, lymphatic drainage remained sluggish, suggesting that different processes are involved in blood and lymphatic vessel impairment within tumours 123 . Investigations into whether immune cells possess a similar ability to remodel dysfunctional tumour lymphatics, in addition to blood vessels, may further illuminate the antitumour effects of cancer immunotherapies.
Finally, tumour vascular normalization may also help to restore aberrant concentrations of ions within the TME, which are largely caused by increased cell turnover and the inadequate removal of intracellular ions released from cancer cells 125, 126 . This ionic imbalance can directly inhibit the functions of effector T cells. A recent study showed that elevations in the extracellular potassium concentration in the TME impairs TCR-driven AKTmTOR (mechanistic target of rapamycin) phosphorylation via the activities of serine/threonine-protein phosphatase 2A (PP2A) 126 , thus inhibiting T cell activation. Similarly, T reg cells that were induced to undergo apoptosis due to oxidative stress were found to release and convert a large amount of ATP to adenosine, which led to the downstream effect of amplifying immuno suppressive signals within the TME 127 . This seminal finding demonstrates that local concentrations of cellular metabolites, such as reactive oxygen species, also have critical roles in regulating the immune TME. The identification of different ionic and metabolic checkpoints further highlights the complexities associated with tumour immune escape, which involves both cellular and acellular elements within the
